Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) and Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.
Analyst Ratings
This is a breakdown of recent recommendations for Sol-Gel Technologies and Intra-Cellular Therapies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sol-Gel Technologies | 0 | 0 | 1 | 0 | 3.00 |
| Intra-Cellular Therapies | 0 | 10 | 2 | 0 | 2.17 |
Sol-Gel Technologies presently has a consensus target price of $40.00, indicating a potential upside of 427.01%. Intra-Cellular Therapies has a consensus target price of $109.70, indicating a potential downside of 16.81%. Given Sol-Gel Technologies’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Sol-Gel Technologies is more favorable than Intra-Cellular Therapies.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sol-Gel Technologies | $11.54 million | 1.83 | -$27.24 million | ($3.80) | -2.00 |
| Intra-Cellular Therapies | $680.50 million | 20.64 | -$139.67 million | ($0.73) | -180.64 |
Sol-Gel Technologies has higher earnings, but lower revenue than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Sol-Gel Technologies, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Sol-Gel Technologies has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.
Institutional & Insider Ownership
26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Sol-Gel Technologies and Intra-Cellular Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sol-Gel Technologies | -81.75% | -27.17% | -22.49% |
| Intra-Cellular Therapies | -14.07% | -9.93% | -8.38% |
Summary
Intra-Cellular Therapies beats Sol-Gel Technologies on 8 of the 14 factors compared between the two stocks.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
